PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire BioLegend, Inc. for $5.3 billion on July 25, 2021. The aggregate purchase price is approximately $5.25 billion, subject to certain working capital and other adjustments. The Aggregate Consideration will be paid 59.5% in cash and 40.5% in shares of PerkinElmer's common stock. PerkinElmer has fully committed bridge financing from Goldman Sachs Bank USA in place for the cash portion of the agreed upon purchase price. On August 11, 2021, PerkinElmer, Inc. (“PerkinElmer”) entered into an unsecured delayed draw term loan credit facility (the “Credit Agreement”) with Bank of America, N.A., as Administrative Agent and the Lenders party thereto. The transaction is subject to subject to regulatory approvals. The parties’ obligations to consummate the Merger are subject to customary closing conditions, including the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and applicable foreign antitrust law. The transaction is expected to close by the end of the 2021. The combination is expected to be accretive to PerkinElmer’s existing revenue growth and margin profile and provide an estimated $0.30 of adjusted earnings per share accretion in the first full year following close and greater than $0.50 in the second year following close. The combined company will generate immediate revenue synergies which are expected to reach $100 million annually by the fifth year following the transaction close and no significant cost synergies are planned. Goldman Sachs & Co. LLC acted as financial advisor and Hal J. Leibowitz, Andrew R. Bonnes, Jeffries Oliver-Li, Steven Barrett, Justin Ochs, Erika Robinson and Nathan Moore, Amy Null, Scott Kilgore, Julie Hogan Rodgers, Bill Caporizzo, Meghan Walsh and Barry Hurewitz of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal advisor for PerkinElmer, Inc. J.P. Morgan Securities LLC acted as financial advisor and Jarrod D. Murphy, Mike Hird, Gabriella Lombardi, Richard Blaylock, Julie Park, Harriet McCartin, Nora Burke, Joel Simon, Joe Fastiggi, Alvin Dunn, Evan Storm, Nancy Fischer, Matt Rabinowitz, Cindy Schlaefer, Kevin Meil, Paula Weber, Laura Latham, Andrea Milano and Michelle Mehok of Pillsbury Winthrop Shaw Pittman LLP acted as legal advisor for BioLegend, Inc. Paul, Weiss, Rifkind, Wharton & Garrison advises Goldman Sachs & Co. LLC in the transaction. PerkinElmer, Inc. (NYSE:PKI) completed the acquisition of BioLegend, Inc. for $5.7 billion on September 17, 2021. PerkinElmer acquired BioLegend net of cash $292.4 million. Cash consideration include $3.3 billion and 14 million shares issued as consideration. It is expected that BioLegend will contribute an incremental $380 million of revenue and $0.30 of adjusted earnings per share accretion to PerkinElmer in fiscal year 2022. PerkinElmer’s expectations for incremental adjusted earnings per share accretion for fiscal year 2022 attributable to BioLegend is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measure without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items PerkinElmer excludes from this non-GAAP measure.